AIM:CLIN

Stock Analysis Report

Executive Summary

Clinigen Group plc operates as a specialty pharmaceutical and services company.

Snowflake

Fundamentals

Reasonable growth potential with imperfect balance sheet.


Similar Companies

Share Price & News

How has Clinigen Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.0%

CLIN

1.7%

GB Life Sciences

-0.2%

GB Market


1 Year Return

2.3%

CLIN

1.1%

GB Life Sciences

-1.8%

GB Market

CLIN matched the Life Sciences industry (1.3%) over the past year.

CLIN outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -1.9% over the past year.


Share holder returns

CLINIndustryMarket
7 Day5.0%1.7%-0.2%
30 Day9.4%4.0%4.0%
90 Day-6.2%0.7%0.5%
1 Year2.9%2.3%1.5%1.1%2.9%-1.8%
3 Year41.7%39.3%19.5%18.6%20.7%6.3%
5 Year117.6%111.2%40.6%38.4%33.2%5.1%

Price Volatility Vs. Market

How volatile is Clinigen Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Clinigen Group undervalued based on future cash flows and its price relative to the stock market?

37%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Clinigen Group's share price is below the future cash flow value, and at a moderate discount (> 20%).

Clinigen Group's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Clinigen Group is overvalued based on earnings compared to the Europe Life Sciences industry average.

Clinigen Group is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.


Price Based on Expected Growth

Clinigen Group is poor value based on expected growth next year.


Price Based on Value of Assets

Clinigen Group is overvalued based on assets compared to the GB Life Sciences industry average.


Next Steps

Future Growth

How is Clinigen Group expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

39.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Clinigen Group's revenue is expected to grow by 9.3% yearly, however this is not considered high growth (20% yearly).

Clinigen Group's earnings are expected to grow significantly at over 20% yearly.

Clinigen Group's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.

Clinigen Group's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.

Clinigen Group's earnings growth is expected to exceed the low risk savings rate of 1.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Clinigen Group is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Clinigen Group performed over the past 5 years?

12.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Clinigen Group's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.

Clinigen Group's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Clinigen Group's 1-year earnings growth is negative, it can't be compared to the Europe Life Sciences industry average.


Return on Equity

Clinigen Group has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Clinigen Group used its assets less efficiently than the Europe Life Sciences industry average last year based on Return on Assets.


Return on Capital Employed

Clinigen Group's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Clinigen Group's financial position?


Financial Position Analysis

Clinigen Group's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Clinigen Group's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Clinigen Group's level of debt (76.6%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (24.6% vs 76.6% today).

Debt is well covered by operating cash flow (20.3%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 6.8x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.7x debt.


Next Steps

Dividend

What is Clinigen Group's current dividend yield, its reliability and sustainability?

1.01%

Expected Dividend Yield


Upcoming Dividend Payment

Purchase Clinigen Group before the 'Buy Limit' to receive their next dividend payment.


Dividend Yield and Payments Analysis

Clinigen Group's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.01%).

Clinigen Group's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (5.42%).

Clinigen Group is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are stable.

Clinigen Group is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Clinigen Group's dividends as it is not paying a notable one for United Kingdom of Great Britain and Northern Ireland.


Future Payout to Shareholders

No need to calculate the sustainability of Clinigen Group's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.


Next Steps

Management

What is the CEO of Clinigen Group's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Shaun Chilton (51yo)

2.8yrs

Tenure

UK£1,358,000

Compensation

Mr. Shaun Edward Chilton has been the Chief Executive Officer of Clinigen Group Plc since November 11, 2016. Mr. Edward served as Group Deputy Chief Executive Officer of Clinigen Group Plc since July 22, 2 ...


CEO Compensation Analysis

Shaun's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.

Shaun's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.8yrs

Average Tenure

51yo

Average Age

The tenure for the Clinigen Group management team is about average.


Board Age and Tenure

3.9yrs

Average Tenure

59yo

Average Age

The tenure for the Clinigen Group board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUK£34,82719 Sep 19
Nicholas Keher
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares3,900
Max PriceUK£8.93
BuyUK£60,00301 Oct 18
Shaun Chilton
EntityIndividual
Role
Chief Executive Officer
CEO & Executive Director
Shares7,101
Max PriceUK£8.45

Ownership Breakdown


Management Team

  • Shaun Chilton (51yo)

    CEO & Executive Director

    • Tenure: 2.8yrs
    • Compensation: UK£1.36m
  • Ivo Timmermans (59yo)

    Chief Medial Officer

    • Tenure: 3.6yrs
  • Nick Keher

    CFO & Director

    • Tenure: 0.5yrs
  • Mark Corbett

    Managing Director of Global Access Division

    • Tenure: 6.2yrs
  • David Bryant

    Director of Corporate Development

    • Tenure: 5.2yrs
  • Johannes Willemse (51yo)

    Chief Commercial Officer

    • Tenure: 0yrs
  • Debra Ainge

    Chief Operating Officer

    • Tenure: 0yrs
  • Jessica Archer

    Global Human Resources Director

    • Tenure: 2.8yrs
  • Matt Parrish

    Head of Investor Relations

    • Tenure: 0yrs
  • Terry Walsh

    Senior Vice President of Clinical Trial Services

    • Tenure: 1.5yrs

Board Members

  • Ian Nicholson (59yo)

    Independent Non-Executive Director

    • Tenure: 7yrs
    • Compensation: UK£70.00k
  • Peter Allen (63yo)

    Independent Non-Executive Chairman

    • Tenure: 7.1yrs
    • Compensation: UK£144.00k
  • Alan Boyd (64yo)

    Non-Executive Director

    • Tenure: 0.8yrs
  • Anne Hyland (58yo)

    Independent Non-Executive Director

    • Tenure: 1.7yrs
    • Compensation: UK£36.00k
  • Shaun Chilton (51yo)

    CEO & Executive Director

    • Tenure: 2.8yrs
    • Compensation: UK£1.36m
  • Nick Keher

    CFO & Director

    • Tenure: 0.5yrs
  • John Hartup (68yo)

    Senior Independent Non-Executive Director

    • Tenure: 0yrs
    • Compensation: UK£70.00k
  • Johannes Willemse (51yo)

    Chief Commercial Officer

    • Tenure: 0yrs

Company Information

Clinigen Group Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clinigen Group Plc
  • Ticker: CLIN
  • Exchange: AIM
  • Founded: 2008
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£1.260b
  • Shares outstanding: 132.47m
  • Website: https://www.clinigengroup.com

Number of Employees


Location

  • Clinigen Group Plc
  • Pitcairn House
  • Crown Square
  • Burton-on-Trent
  • Staffordshire
  • DE14 2WW
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLINAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPSep 2012
CLIG.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDSep 2012
78CDB (Deutsche Boerse AG)YesOrdinary SharesDEEURSep 2012

Biography

Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Com ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 21:26
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.